Rules concerning biological products eased

Published: 2009-07-20 06:57:00

Updated: 2009-07-20 06:57:00

The Korea Food and Drug Administration said on July 15 that some of the rules concerning the license of biological products, including biosimilars, have been eased for ameliorating unnecessary procedures in the screening process for drug approval and making the definition of biosimilars more clea...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK